Direkt zum Inhalt
Merck
  • Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Hepatology (Baltimore, Md.) (2014-08-22)
Douglas A Simonetto, Hui-yin Yang, Meng Yin, Thiago M de Assuncao, Jung Hee Kwon, Moira Hilscher, Shuchong Pan, Liu Yang, Yan Bi, Arthur Beyder, Sheng Cao, Robert D Simari, Richard Ehman, Patrick S Kamath, Vijay H Shah
ZUSAMMENFASSUNG

Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; however, the mechanisms involved in this process are not well understood. We developed a murine experimental model of congestive hepatopathy through partial ligation of the inferior vena cava (pIVCL). C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22α-TFPI) were subjected to pIVCL or sham. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, real-time polymerase chain reaction, and western blot assays. Hepatic fibrosis and portal pressure were significantly increased after pIVCL concurrent with hepatic stellate cell (HSC) activation. Liver stiffness, as assessed by magnetic resonance elastography, correlated with portal pressure and preceded fibrosis in our model. Hepatic sinusoidal thrombosis as evidenced by fibrin deposition was demonstrated both in mice after pIVCL as well as in humans with congestive hepatopathy. Warfarin treatment and TFPI overexpression both had a protective effect on fibrosis development and HSC activation after pIVCL. In vitro studies show that congestion stimulates HSC fibronectin (FN) fibril assembly through direct effects of thrombi as well as by virtue of mechanical strain. Pretreatment with either Mab13 or Cytochalasin-D, to inhibit β-integrin or actin polymerization, respectively, significantly reduced fibrin and stretch-induced FN fibril assembly. Chronic hepatic congestion leads to sinusoidal thrombosis and strain, which in turn promote hepatic fibrosis. These studies mechanistically link congestive hepatopathy to hepatic fibrosis.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Natriumdodecylsulfat, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Natriumdodecylsulfat, ACS reagent, ≥99.0%
Sigma-Aldrich
Natriumdodecylsulfat -Lösung, BioUltra, Molecular Biology, 10% in H2O
Sigma-Aldrich
Natriumdodecylsulfat, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, BioUltra, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
Natriumdodecylsulfat -Lösung, BioUltra, 20% in H2O
Supelco
Natriumdodecylsulfat, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
Supelco
Natriumdodecylsulfat, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
Natriumdodecylsulfat, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, ≥98.0% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
Natriumdodecylsulfat, ≥90% ((Assay))
Sigma-Aldrich
Natriumdodecylsulfat, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
2,2′-Bichinolin-4,4′-dicarbonsäure Dinatriumsalz Dihydrat, ≥98% (HPLC)
Sigma-Aldrich
21-Hydroxyprogesteron, ≥97% (HPLC)
Natriumlaurylsulfat, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Natriumdodecylsulfat, ≥98.0% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC), free-flowing, Redi-Dri